Drug Trial Radar · NCT07611110
AZD2265 Compared With Standard of Care in PSMA-positive Metastatic Castration-resistant Prostate Cancer (VECTRA-01)
Last checked: Nov 19, 2026Latest source record: Oct 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
670
Planned (sponsor's estimate)
Start
May 4, 2026
Primary completion
Jun 4, 2029
Study completion Jun 6, 2030
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- May 28, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Single (outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- Male only, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The intention of the study is to demonstrate superiority of AZD2265 relative to standard of care treatments by assessment of radiographic progression-free survival (rPFS) and overall survival (OS) in participants with mCRPC.
Conditions
- Metastatic Castration-resistant Prostate Cancer
Interventions
Actinium (225Ac) zadavotide guraxetan (AZD2265 [FPI-2265])Drug
IV
CabazitaxelDrug
IV in combination with oral prednisone/prednisolone
AbirateroneDrug
Oral in combination with prednisone/prednisolone
EnzalutamideDrug
Oral
ApalutamideDrug
Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)
DarolutamideDrug
Oral; Available only to participants randomized under Protocol Version 2.0; not offered to participants randomized under Protocol Version 3.0 (04 June 2026)
DeutenzalutamideDrug
Oral; available in China only
Radium-223Drug
IV
Primary outcomes
What the sponsor says the trial is designed to measure.
- Radiographic Progression-Free Survival (rPFS)Time frame: From randomization until first radiographic progression per RECIST 1.1/PCWG3 by BICR, or death from any cause, whichever occurs first (up to approximately 33 months)
- Overall Survival (OS)Time frame: From randomization until death from any cause (up to approximately 33 months)
Locations
151 sites in 24 countries. Site status is shown where the registry gives one.
Research Site
Dothan, Alabama · Recruiting
Research Site
Phoenix, Arizona · Withdrawn
Research Site
Duarte, California · Recruiting
Research Site
Irvine, California · Not yet recruiting
Research Site
Newport Beach, California · Recruiting
Research Site
San Francisco, California · Recruiting
Research Site
Aurora, Colorado · Not yet recruiting
Research Site
Miami, Florida · Recruiting
Research Site
O'Fallon, Illinois · Not yet recruiting
Research Site
Metairie, Louisiana · Recruiting
Research Site
Westbrook, Maine · Not yet recruiting
Research Site
Detroit, Michigan · Withdrawn
Research Site
Grand Rapids, Michigan · Not yet recruiting
Research Site
St Louis, Missouri · Not yet recruiting
Research Site
Omaha, Nebraska · Recruiting
Research Site
Albuquerque, New Mexico · Not yet recruiting
Research Site
New Hyde Park, New York · Not yet recruiting
Research Site
New York, New York · Recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Cleveland, Ohio · Not yet recruiting
Research Site
Dayton, Ohio · Not yet recruiting
Research Site
Portland, Oregon · Not yet recruiting
Research Site
Pittsburgh, Pennsylvania · Recruiting
Research Site
Myrtle Beach, South Carolina · Recruiting
Research Site
Nashville, Tennessee · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Salt Lake City, Utah · Suspended
Research Site
Tacoma, Washington · Not yet recruiting
Research Site
Darlinghurst, Australia · Not yet recruiting
Research Site
Kurralta Park, Australia · Not yet recruiting
Research Site
Melbourne, Australia · Recruiting
Research Site
Murdoch, Australia · Not yet recruiting
Research Site
Linz, Austria · Not yet recruiting
Research Site
Salzburg, Austria · Not yet recruiting
Research Site
Vienna, Austria · Not yet recruiting
Research Site
Ghent, Belgium · Not yet recruiting
Research Site
Leuven, Belgium · Not yet recruiting
Research Site
Liège, Belgium · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Research Site
São Paulo, Brazil · Not yet recruiting
Showing 40 of 151 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.